Click Therapeutics Inc is sharpening its positioning around Prescription Drug Use-Related Software (PDURS) as a way to boost the value of established pharmaceutical brands. In a recent LinkedIn post referencing a collaborative piece with IQVIA, the company framed PDURS as a bridge between digital innovation and measurable commercial outcomes across life sciences.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Click highlighted mounting industry pressures, including a relatively steady pace of about 50 U.S. drug approvals per year and an estimated $300 billion revenue impact from patent expirations by 2030. The company also pointed to growing payer demands for stronger clinical and economic evidence, arguing that software-enhanced therapies could help address these challenges.
According to the post, software can now be incorporated into FDA-authorized labels as part of a “Software-Enhanced Drug™” model, enabling integration of software-as-a-medical-device into standard care pathways. This approach is positioned to help pharmaceutical companies improve patient outcomes, differentiate efficacy beyond pharmacotherapy and extend brand lifecycles.
Click Therapeutics is aligning its digital therapeutics and SaMD offerings with PDURS-related regulatory and evidentiary frameworks, aiming to serve as an enabling partner for pharma. By embedding its software into drug labels and commercialization workflows, the company seeks to support co-developed products, licensing structures and SaaS-like models that could deepen its role in digital health and pharma innovation.
If PDURS adoption expands and payers acknowledge the added value of software-driven interventions, Click’s platform could become increasingly important to branded drug strategies. Overall, the week underscored the company’s strategic focus on Software-Enhanced Drugs™ as a lever for defending and growing pharma revenues in a patent-constrained environment.